Back to search

Article

An advanced IVB lung adenocarcinoma patient with KRAS mutations, benefited from camrelizumab combined with anti-angiogenic agents for therapy: a case report

2024-07-21

Abstract excerpt

<h4>Purpose: </h4> Although the presence of Kirsten rat sarcoma virus (KRAS) mutations predicts of a lack of benefit from epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) therapy for none small cell cancer (NSCLC), it may be more sensitive to programmed combination therapy with cell death 1 (PD-1)/programmed death-ligand 1 (PD-L1) inhibitors + anti-angiogenesis. Recent treatment guidelines a...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
d65da0b0-620f-5783-8ad7-3a6b18037eac
DOI
10.22541/au.172155319.95213431/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
An advanced IVB lung adenocarcinoma patient with KRAS mutations, benefited from camrelizumab combined with anti-angiogenic agents for therapy: a case reportDOI 10.22541/au.172155319.95213431/v1
An advanced IVB lung adenocarcinoma patient with KRAS mutations, benefited from camrelizumab combined with anti- angiogenic agents for therapy: a case reportSemantic proximity
An Advanced IVB Lung Adenocarcinoma Patient With KRAS Mutations, Benefited From Camrelizumab Combined With Anti-Angiogenic Agents for Therapy: A Case Report.Semantic proximity
[Annual therapeutic advances in advanced non-small cell lung cancer in 2024].Semantic proximity
Targeted combination of Bevacizumab demonstrates superior efficacy for stage IV Adenocarcinoma of the lung with EGFR mutation: A Real World StudySemantic proximity
Targeted therapeutic options in early and metastatic NSCLC-overview.Semantic proximity
Exploration of efficacy of different therapy regimens for advanced NSCLC patients with KRAS mutation in the first-line treatment.Semantic proximity
Efficacy and safety of immuno-chemotherapy in patients with advanced non-small-cell lung cancer harboring oncogenic mutations: a multicenter retrospective study.Semantic proximity
Evaluating the Efficacy of EGFR-TKIs Combined With Radiotherapy in Advanced Lung Adenocarcinoma Patients With EGFR Mutation: A Retrospective Study.Semantic proximity
Efficacy of first-line immune checkpoint inhibitor and anti-angiogenic agent combination therapy for Kirsten rat sarcoma viral antigen-mutant advanced non-small-cell lung cancer: a systematic review and network meta-analysis.Semantic proximity
Differential Benefit of Immune Checkpoint Blockade by<i>KRAS</i>Mutation Status in Metastatic Lung Adenocarcinoma: Validation from an Extended Swedish CohortSemantic proximity
Decoding KRAS mutation in non-small cell lung cancer patients receiving immunotherapy: A retrospective institutional comparison and literature review.Semantic proximity
Real-World Treatment Patterns and Effectiveness of Targeted and Immune Checkpoint Inhibitor-Based Systemic Therapy in BRAF Mutation-Positive NSCLCSemantic proximity
Select a neighboring publication to make it the new centre.